Arvinas, Inc. Profile Avatar - Palmy Investing

Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera…

Biotechnology
US, New Haven [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Arvinas, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ARVN's Analysis
CIK: 1655759 CUSIP: 04335A105 ISIN: US04335A1051 LEI: - UEI: -
Secondary Listings
ARVN has no secondary listings inside our databases.